Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
about
Delayed access to treatments for rare diseases: who's to blame?Melanoma Brain Metastasis: Mechanisms, Models, and MedicineIrradiated riboflavin diminishes the aggressiveness of melanoma in vitro and in vivoA protein deep sequencing evaluation of metastatic melanoma tissuesSystemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma.Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis.Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.Metastatic malignant melanoma with peritoneal seeding in a young woman: A case reportEnhancement of electroporation facilitated immunogene therapy via T-reg depletion.Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport.Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective studyLong-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma.Malignant melanoma scrotal metastasis: The importance of the genital examination.The influence of tumor regression, solar elastosis, and patient age on pathologists' interpretation of melanocytic skin lesions.Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals.Investigation of the cytotoxic implications of metal chelators against melanoma and approaches to improve the cytotoxicity profiles of metal coordinating agents.Melanoma-derived IL-1 converts vascular endothelium to a proinflammatory and procoagulatory phenotype via NFκB activation.Primary gastric melanoma: case report of a rare malignancyFocus on cutaneous and uveal melanoma specificities.Challenges in the delivery of therapies to melanoma brain metastases.Emerging growth factor receptor antagonists for the treatment of advanced melanoma.Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.The HGF/SF Mouse Model of UV-Induced Melanoma as an In Vivo Sensor for Metastasis-Regulating Gene.Stereotactic Radiosurgery and Ipilimumab Versus Stereotactic Radiosurgery Alone in Melanoma Brain Metastases.Current surgical management of melanoma metastases to the lung.Melanoma metastasis to the gastric mucosa preceded by guillain-barré as a paraneoplastic syndrome.Malignant melanoma with cavitary pulmonary metastasis: Diagnostic dilemma resolved by FDG PET/CT guided biopsy.Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors.The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells.Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.A structural perspective on the interactions of TRAF6 and Basigin during the onset of melanoma: A molecular dynamics simulation study.Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases.Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.REGγ accelerates melanoma formation by regulating Wnt/β-catenin signalling pathway.
P2860
Q26864797-0DC65637-B19A-4636-809C-BB02236099ECQ28069421-BF931DCA-C71F-4B65-A529-A8E50E6A259CQ28485143-790E7DE4-D576-44E5-9756-381E99C1681AQ28546229-84CA7D40-680F-4D70-B6AD-F51E8211CA35Q30940472-31C7681B-EA90-4283-ADFA-309DE8D013BAQ31089944-140EC92C-14E1-4577-9F9E-948761B94B61Q33605879-DA66D325-3C42-4BA6-822E-D2E009849F62Q33686532-6FF4FA6D-1FBB-409C-909A-084E07B760B9Q34072036-37DEB598-170D-4467-AFAE-928E4DA91FDCQ34413011-6743BCCE-17A3-4037-A693-631A1DDD08D1Q34629376-46FD28E7-0A9F-488D-8EF2-493A38E1ED87Q36028552-4F40EBC7-CD46-45FD-A14D-824D538FD18FQ36785750-1D8E7F18-7A5D-4268-89BA-753B6AE9C060Q37544136-EEE201E3-891B-4067-B328-932F122B4837Q37614077-BA37FA60-97C7-4B91-8DEA-9266129D165BQ37615286-DF40D227-422F-4D24-8ADB-693815FEFCF0Q37708829-16C23939-45EF-46E0-BC47-BFC8B0DA58C5Q38575000-05D40215-24C6-444A-8D3A-24B7D2E15F57Q38729911-4E71067B-596C-4E19-B3CC-9AE975B541D5Q38759275-16E3B912-EF08-4B9D-A4AA-60C5B218EBA6Q38973890-8F7720AB-46B5-48A4-8C88-444E2DE77761Q39306900-A96ABD44-315E-45B8-A740-132B91D38B27Q39312161-C4A16A7C-4B3F-4833-A7E8-FDBABC460213Q39331752-9B1962DC-0533-485A-BEB9-D705FC856BFCQ39340696-A2F6D22C-79B9-4E6C-909C-3E2287EB4815Q40122051-AB3C1AA9-5EDC-43E3-B4A2-899C84903B0CQ40629543-D96DD1A7-2ADB-4C6F-9A70-1CB8B855D95EQ41450925-CA31353F-4427-4813-9F9C-2B9E5C8CBD71Q41573204-DA330F13-2FDA-4EE2-9596-0F157CB08499Q41671606-73681702-572C-4D67-A2FF-DB28A2FC2F6EQ41858622-BA00E723-661A-4648-981F-7B20B26B3A0BQ41966726-09EF11FD-BF2B-4AB6-B5DD-A07BD62274C5Q42867937-6CACC521-2FF0-4E14-AFD5-12BD49FC3A30Q47149194-D7239F3E-9947-4310-A56D-4E2C83746CE0Q47396492-021014EB-51C5-4E5C-AB5B-56A81C9CE5FCQ47828100-7306B7DD-AC52-45E8-AE4B-745A95187371Q48059710-E4651A5C-0237-4B1E-B94B-60D72B704808Q48108646-55CDAC4F-9101-48DB-9975-2A2A944DD7BCQ48164881-48A012C7-79AF-4E10-84A7-08ADAC9F2E91Q48291998-D59E79C6-9FC7-484E-A045-1F0176D948DE
P2860
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@ast
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@en
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@nl
type
label
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@ast
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@en
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@nl
prefLabel
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@ast
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@en
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@nl
P2860
P356
P1433
P1476
Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors
@en
P2093
P2860
P304
P356
10.1155/2012/647684
P577
2012-06-27T00:00:00Z